一位身着海军蓝西装、系浅蓝色领带、穿着白衬衫的男士,站在模糊的商法事务所背景前微笑着。

安德鲁-E-罗林斯

合作伙伴

安德鲁-E-罗林斯

合作伙伴

Andrew E. Rawlins is a partner and transactional lawyer with over 30 years of experience in intellectual property, focusing his practice on technology-intensive matters. He is a member of the Health Care & Life Sciences Sector and the Automotive Industry Team.

Andrew structures and negotiates technology agreements to create business relationships between companies that leverage technology and create synergistic opportunities. Using his experience and focus on technology transactions, he works with clients to identify critical issues and efficiently complete deals. Throughout his career, he has assisted clients with other strategic intellectual-property issues, such as due diligence in commercial transactions, patent procurement and portfolio management, and opinions on validity and infringement.

His practice is informed by his prior experience as a patent examiner at the United States Patent and Trademark Office and having conducted patent litigation, including trials and arguments before various trial courts and the U.S. Court of Appeals for the Federal Circuit.

Andrew has particular experience in a variety of technology fields, including pharmaceuticals, biotechnology, medical devices, automotive, and consumer electronics.

奖项与表彰

  • 杰出律师,汤森路透(2025年)
  • Recommended in the categories of patent licensing and transactional (2014 and 2015) and patent portfolio management and licensing (2016) by The Legal 500
  • Peer Review Rated in Martindale-Hubbell’s peer review rating system
  • Selected as a finalist for Washington Business Journal’s 2008 Top Washington Lawyers awards program
  • Advisory board member for BNA’s Medical Devices Law & Industry Report
  • Former member of the intellectual property advisory board for Law360

附属机构

  • 美国知识产权法协会
  • 美国律师协会
2024年9月17日 交易与胜利

Foley Represents TCGX as Lead Investor in $105M Series B Financing for Pathalys Pharma

Foley & Lardner LLP represented TCG Crossover (TCGX) as the lead investor in the $105 million Series B financing for Pathalys Pharma Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease.
2024 年 9 月 3 日 交易与胜利

富理达代表 ARCHIMED 收购 Irrimax 公司

Foley & Lardner LLP 最近代表全球私募股权医疗保健专业公司 ARCHIMED 收购了 Irrimax 公司,包括其控股公司 Innovation Technologies,收购金额未披露。
2024年4月11日 交易与胜利

Foley 代表 ARCHIMED 收购创新护肤品公司 Cellese 的多数股权

Foley & Lardner LLP 代表全球私募股权医疗保健专业公司 ARCHIMED 收购了 Cellese 的多数股权,Cellese 是一家以 AnteAGE 品牌销售的创新外用皮肤美容产品的开发商。
September 27, 2023 Deals and Wins

Foley Represents Bioluminescence Ventures as Lead Investor in ReCode Therapeutics Series B Funding Extension

Foley & Lardner LLP represented Bioluminescence Ventures as the lead investor in the $50 million Series B funding extension for ReCode Therapeutics.
October 5, 2022 Deals and Wins

Foley Represents Hanwha Impact Partners as Lead Investor in $121M Series C Funding for Cellarity

Foley & Lardner LLP recently represented Hanwha Impact Partners as a lead investor in the $121 million Series C funding round for Cellarity, a developer of cell behavior therapies.
September 14, 2022 Deals and Wins

Foley Represents TCG Crossover as Lead Investor in EUR 49.2M Crossover Financing for Abivax

Foley & Lardner LLP recently represented TCG Crossover (TCGX) as the lead investor in the successful, oversubscribed EUR 49.2 million crossover financing for Abivax.